Albireo Pharma, Inc.

NasdaqCM:ALBO Stock Report

Market Cap: US$921.1m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Albireo Pharma Management

Management criteria checks 2/4

Key information

Ron Cooper

Chief executive officer

US$6.0m

Total compensation

CEO salary percentage9.77%
CEO tenure7.7yrs
CEO ownership0.2%
Management average tenure4.2yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely

Jan 02
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely

Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt

Oct 25
Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt

Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome

Oct 11

Albireo Pharma: Assessing The Sagard Deal

Oct 03

Albireo gains on royalty agreement for pruritus therapy

Sep 22

Albireo gets reimbursed access to liver disease drug Bylvay in Italy

Sep 06

These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts

Aug 23
These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts

Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M

Aug 15

Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation

Jul 22

Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt

May 10
Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt

Albireo: A Speculative Play With Upside

May 03

Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?

Feb 02
Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?

Albireo: Successful And Accelerating Global Launch Drives Sales Revenue

Jan 31

Albireo: Reasons For A Successful Transformation Into A Commercial Company

Nov 24

Albireo Pharma: A Post Approval Assessment

Aug 09

Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress

Jun 21

Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year

Jun 11
Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year

Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts

Feb 27
Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts

CEO Compensation Analysis

How has Ron Cooper's remuneration changed compared to Albireo Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2022n/an/a

-US$131m

Jun 30 2022n/an/a

-US$36m

Mar 31 2022n/an/a

-US$33m

Dec 31 2021US$6mUS$590k

-US$34m

Sep 30 2021n/an/a

-US$48m

Jun 30 2021n/an/a

-US$136m

Mar 31 2021n/an/a

-US$120m

Dec 31 2020US$3mUS$570k

-US$108m

Sep 30 2020n/an/a

-US$90m

Jun 30 2020n/an/a

-US$82m

Mar 31 2020n/an/a

-US$78m

Dec 31 2019US$3mUS$551k

-US$63m

Sep 30 2019n/an/a

-US$71m

Jun 30 2019n/an/a

-US$63m

Mar 31 2019n/an/a

-US$61m

Dec 31 2018US$4mUS$530k

-US$46m

Sep 30 2018n/an/a

-US$35m

Jun 30 2018n/an/a

-US$28m

Mar 31 2018n/an/a

-US$19m

Dec 31 2017US$2mUS$460k

-US$24m

Sep 30 2017n/an/a

-US$31m

Jun 30 2017n/an/a

-US$28m

Mar 31 2017n/an/a

-US$20m

Dec 31 2016US$4mUS$400k

-US$16m

Compensation vs Market: Ron's total compensation ($USD6.04M) is above average for companies of similar size in the US market ($USD3.58M).

Compensation vs Earnings: Ron's compensation has increased whilst the company is unprofitable.

CEO

Ron Cooper (59 yo)

7.7yrs
Tenure
US$6,041,334
Compensation

Mr. Ronald H. W. Cooper, also known as Ron, serves as Independent Director at Generation Bio Co. since March 2021. He has been the Chief Executive Officer and President of Albireo Pharma Inc. since July 20...

Leadership Team

NamePositionTenureCompensationOwnership
Ronald H. Cooper
CEO, President & Director7.7yrsUS$6.04m0.16%
$ 1.5m
Simon Nicolas Harford
CFO & Treasurer4.4yrsUS$1.71m0.066%
$ 606.6k
Martha Carter
Chief Regulatory Officer6.3yrsUS$1.73m0.018%
$ 161.4k
Per-Goran Gillberg
Co-Founder & VP of Developmentno datano datano data
Jan Mattsson
Chief Scientific Officer15.2yrsUS$1.40m0.17%
$ 1.6m
Joan Connolly
Chief Technology Officer1.9yrsno datano data
Jason Duncan
Chief Legal Officer4.8yrsno data0.016%
$ 145.5k
Michelle Graham
Chief Human Resources Officer3.3yrsno data0.027%
$ 244.7k
Kristina Torfgard
VP & Global Project Headno datano datano data
Pamela Stephenson
Chief Commercial Officer4yrsUS$1.96m0.11%
$ 982.0k
Constantine Chinoporos
Chief Business Officer1.3yrsno datano data
Paul Streck
Chief Medical Officerless than a yearno datano data
4.2yrs
Average Tenure
58.5yo
Average Age

Experienced Management: ALBO's management team is considered experienced (4.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ronald H. Cooper
CEO, President & Director7.5yrsUS$6.04m0.16%
$ 1.5m
David Chiswell
Independent Chairman of the Board15.1yrsUS$282.44k0.27%
$ 2.5m
Davey Scoon
Independent Director6.3yrsUS$266.82k0.14%
$ 1.3m
Michael Gutch
Independent Director7.4yrsUS$264.94k0.13%
$ 1.2m
Craig Hopkinson
Directorless than a yearno datano data
Habib Dable
Independent Directorless than a yearno datano data
Stephanie Okey
Independent Director4.8yrsUS$249.94k0.14%
$ 1.3m
Susan Alesina
Directorless than a yearno datano data
5.5yrs
Average Tenure
59yo
Average Age

Experienced Board: ALBO's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/03/03 08:48
End of Day Share Price 2023/03/02 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Albireo Pharma, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
null nullGuggenheim Securities, LLC
Seamus FernandezGuggenheim Securities, LLC